Rensselaer's Institutional Biosafety Committee (IBC) provides an environment in which scientific research at Rensselaer can advance in a safe, informed and ethical manner.
Rensselaer is responsible, under federal law (section III of the NIH Guidelines for Research Involving Recombinant DNA Molecules), for the approval and supervision of the appropriate performance of all research and teaching activities that involve recombinant DNA research.
- Rensselaer's IBC is responsible for ensuring the performance of safe and appropriate research procedures.
- The IBC reports to the Rensselaer Institutional Official (IO) of record who is currently the Acting Vice President for Research.
- IBC oversight of all research performed by Rensselaer faculty, staff and students is mandated by the NIH Office of Biotechnology Activities (OBA) and, in certain cases, by the Centers for Disease Control and Prevention (CDC).
- Rensselaer provides occupational health guidance and care for all researchers and staff.
The IBC reviews and monitors all research involving the following materials, regardless of the source of funding:
- Recombinant DNA or recombinant RNA molecules
- Plasmids and transposons
- Viruses and viral vectors
- Human and non-human primate cells, tissues and fluids
- All pathogens and select agents
Blanca Barquera, Ph.D., Chair
Robert Hull, Ph.D., Institutional Official (IO)
Jack Huang, Ph.D., Director, Grants and Compliance
- Proposed research protocols must be submitted by the Principal Investigator for review.
- The biosafety level of the research is classified according to federal guidelines; this classification determines the criteria for safe performance of the proposed work.
- Send your protocols to email@example.com. The proposed procedures are reviewed to ensure that the work will be performed with appropriate personnel training, required facility safeguards and adequate biosafety procedures.
Questions and Forms Submission: Direct all inquiries to firstname.lastname@example.org.